Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
Phase 2: testing Tirzepatide for Sarcoma,Soft Tissue
This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic. The study will enroll young adults (18-39 years) with soft tissue or bone sarcoma who are overweight (body-mass index (BMI) 25-29.9 kg/m² with ≥1 cardiovascular risk factor) or obese (body-mass index (BMI) ≥30 kg/m²), have completed Dox-based chemotherapy (≥300 mg/m²) approximately three months prior to enrollment, and have preserved LVEF (≥50%) preenrollment.
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Tirzepatide. The registry lists allocation as na. This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic.
They plan to enroll about 30 people at Houston. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study
Primary outcome (registry wording): Safety and Adverse Events (AEs)
Who it is for (from inclusion criteria)
Ages 18 Years to 39 Years
Age 18-39 years at enrollment
Histologically confirmed soft tissue or bone sarcoma with treatment that included Dox ≥ 300 mg/m²
Completed chemotherapy 3 months prior to enrollment; patient must be in remission at the time of enrollment with no planned systemic therapy, radiation therapy, or surgical oncologic intervention anticipated within the next 12 months
Overweight (body-mass index (BMI) 25-29.9 kg/m² with ≥1 cardiovascular risk factor) or obese (body-mass index (BMI) ≥30 kg/m²) at the time of enrollment
LVEF ≥ 50% at the time of enrollment with no symptoms of heart failure (NYHA class I-II)
how well you can do daily activities (ECOG score) ≤2 (equivalent to Karnofsky ≥60%) at the time of enrollment
Ongoing active malignancy or ongoing systemic therapy for cancer treatment
Patients who have not recovered from side effects due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia
History of pancreatitis, medullary thyroid carcinoma, or MEN2
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07874828?
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07874828?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.